search
Back to results

Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria (DCHGD)

Primary Purpose

Gender Dysphoria

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MRI
Sponsored by
Hôpital le Vinatier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Gender Dysphoria focused on measuring gender dysphoria, neuroimaging, hormone-surgical reassignment

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • gender dysphoric subjects MtF
  • right handed
  • androphilic orientation
  • without hormone therapy

Control group of male subjects:

  • right handed
  • without any psychiatric or medical history
  • androphilic orientation

Exclusion Criteria:

  • MRI contraindication
  • vulnerable adults
  • mental retardation
  • psychiatric or neurological disease including autism spectrum disorders, psychotropic medication
  • hormonal or genetic condition

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Other

    Arm Label

    gender dysphoria subjects

    control subjects

    Arm Description

    Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy

    Control group inclusions, of open-label patients without gender dysphoria.

    Outcomes

    Primary Outcome Measures

    Brain connectome 6 months after the hormone therapy beginning
    Structural and functional MRI before and after 6 months of hormone therapy will be analysed in order to make a comparison before/after

    Secondary Outcome Measures

    Brain connectome in gender dysphoric and control subjects
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. At baseline, these networks will be compared between dysphoric and control subjects.
    Gender dysphoria phenotype description
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. Correlations will be made at baseline between brain connectome of the dysphoric subjects and testosteronemia, and developmental measures : age at beginning of gender dysphoria, finger lenghth D2/D4 ratio, birth weight, laterality using Edimbourg scale.
    Brain connectome variations
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. Evolutions of the brain connectome of dysphoric subjects will be compared after 6 months of hormone therapy, taking into acount gender dysphoria decrease measured using Utrecht Gender Dysphoria Scale.

    Full Information

    First Posted
    February 18, 2020
    Last Updated
    March 23, 2022
    Sponsor
    Hôpital le Vinatier
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04309760
    Brief Title
    Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria
    Acronym
    DCHGD
    Official Title
    Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2022
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    the patients are now followed in another hospital. The study is discontinued
    Study Start Date
    February 2021 (Anticipated)
    Primary Completion Date
    June 15, 2021 (Anticipated)
    Study Completion Date
    March 15, 2022 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hôpital le Vinatier

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of the research is to study longitudinally the effects of reassignment hormonotherapy on the connectome of MtF (biological men who are transitioning to the female gender) dysphoric subjects after 6 months of hormone therapy. The subjects will be compared to a control group of healthy subjects taking into account sexual orientation
    Detailed Description
    The pathophysiology of gender dysphoria is still poorly understood, but a number of clues point to an origin derived from biological and environmental factors, particularly studies of twins, birth order, and family groups. Several explanatory models have been put forward. In particular, the differentiation of genitals taking place in the first half of pregnancy while that of the brain in the second makes it possible to imagine a different differentiation between the external phenotype and the cerebral gender. Several developmental features have thus been found in gender dysphoric subjects, including the finger length ratio D2 / D4, lateralization. Some neuroimaging studies have shown brain features in gender dysphoric subjects that seem original compared to control subjects. Nevertheless, the results are scarce, poorly reproduced, and for some, the differences highlighted may be related to phenotypic variability including the non-consideration of sexual orientation. Moreover, some of these studies combine subjects treated or not with hormone therapy which is a bias because it is likely that hormone therapy may have structural and functional effects on brain function. The investigators team deals with dysphoric gender issues as part of a coordinated course of hormone-surgical reassignment. We wish to better characterize the brain effects, at the level of the "connectome" of the reassignment hormone therapy in a population of dysphoric subjects, taking into account signs of pre-natal hormonal impregnation (D2 / D4 ratio), developmental features (onset of dysphoria, lateralization, size), and controlling sexual orientation as a potential confounding factor. The aim of the research is then to study longitudinally the effects of reassignment hormonotherapy on the connectome of MtF dysphoric subjects after 6 months of hormone therapy. The subjects will be compared to a control group of healthy subjects taking into account sexual orientation. This is a prospective longitudinal study that includes, in a consecutive manner, open-label patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy; the imaging data will be compared to a control group (n = 20).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gender Dysphoria
    Keywords
    gender dysphoria, neuroimaging, hormone-surgical reassignment

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Comparison between Mtf and control subjects.
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    gender dysphoria subjects
    Arm Type
    Active Comparator
    Arm Description
    Patients with MtF gender dysphoria (biological men who are transitioning to the female gender) attending the forensic psychiatric consultation for a request for hormone-surgical reassignment. Subjects will receive initial clinical assessment and MRI before and 6 months after initiation of hormone therapy
    Arm Title
    control subjects
    Arm Type
    Other
    Arm Description
    Control group inclusions, of open-label patients without gender dysphoria.
    Intervention Type
    Other
    Intervention Name(s)
    MRI
    Intervention Description
    Subjects will receive structural and functional (resting state) MRI
    Primary Outcome Measure Information:
    Title
    Brain connectome 6 months after the hormone therapy beginning
    Description
    Structural and functional MRI before and after 6 months of hormone therapy will be analysed in order to make a comparison before/after
    Time Frame
    6 months after the beginning of the hormone therapy
    Secondary Outcome Measure Information:
    Title
    Brain connectome in gender dysphoric and control subjects
    Description
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. At baseline, these networks will be compared between dysphoric and control subjects.
    Time Frame
    baseline
    Title
    Gender dysphoria phenotype description
    Description
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. Correlations will be made at baseline between brain connectome of the dysphoric subjects and testosteronemia, and developmental measures : age at beginning of gender dysphoria, finger lenghth D2/D4 ratio, birth weight, laterality using Edimbourg scale.
    Time Frame
    baseline and 6 months after the beginning of the hormone therapy
    Title
    Brain connectome variations
    Description
    The MRI images will be analysed in order to construct a brain " connectome " which reflects brain connectivity, using the graph theory. Evolutions of the brain connectome of dysphoric subjects will be compared after 6 months of hormone therapy, taking into acount gender dysphoria decrease measured using Utrecht Gender Dysphoria Scale.
    Time Frame
    6 months after the beginning of the hormone therapy

    10. Eligibility

    Sex
    Male
    Gender Based
    Yes
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: gender dysphoric subjects MtF right handed androphilic orientation without hormone therapy Control group of male subjects: right handed without any psychiatric or medical history androphilic orientation Exclusion Criteria: MRI contraindication vulnerable adults mental retardation psychiatric or neurological disease including autism spectrum disorders, psychotropic medication hormonal or genetic condition

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Developmental Correlates and Hormone Therapy Effects in Gender Dysphoria

    We'll reach out to this number within 24 hrs